These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27418432)

  • 21. Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series.
    Schuemie MJ; Trifirò G; Coloma PM; Ryan PB; Madigan D
    Stat Methods Med Res; 2016 Dec; 25(6):2577-2592. PubMed ID: 24685766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A method for systematic discovery of adverse drug events from clinical notes.
    Wang G; Jung K; Winnenburg R; Shah NH
    J Am Med Inform Assoc; 2015 Nov; 22(6):1196-204. PubMed ID: 26232442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
    Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
    J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity-induced modification of treatment: what is in a name?
    Kok DE; Winkels RM; van Herpen CM; Kampman E
    Eur J Cancer; 2018 Nov; 104():145-150. PubMed ID: 30352382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healthcare databases in Europe for studying medicine use and safety during pregnancy.
    Charlton RA; Neville AJ; Jordan S; Pierini A; Damase-Michel C; Klungsøyr K; Andersen AM; Hansen AV; Gini R; Bos JH; Puccini A; Hurault-Delarue C; Brooks CJ; de Jong-van den Berg LT; de Vries CS
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):586-94. PubMed ID: 24664855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.
    Baker MA; Nguyen M; Cole DV; Lee GM; Lieu TA
    Vaccine; 2013 Dec; 31 Suppl 10():K98-112. PubMed ID: 24331080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.
    Moore TJ; Furberg CD
    Drug Saf; 2015 Jul; 38(7):601-10. PubMed ID: 26025018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using 'big data' to validate claims made in the pharmaceutical approval process.
    Wasser T; Haynes K; Barron J; Cziraky M
    J Med Econ; 2015; 18(12):1013-9. PubMed ID: 26548546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medication safety research by observational study design.
    Lao KS; Chui CS; Man KK; Lau WC; Chan EW; Wong IC
    Int J Clin Pharm; 2016 Jun; 38(3):676-84. PubMed ID: 27003827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Facilitating phenotype transfer using a common data model.
    Hripcsak G; Shang N; Peissig PL; Rasmussen LV; Liu C; Benoit B; Carroll RJ; Carrell DS; Denny JC; Dikilitas O; Gainer VS; Howell KM; Klann JG; Kullo IJ; Lingren T; Mentch FD; Murphy SN; Natarajan K; Pacheco JA; Wei WQ; Wiley K; Weng C
    J Biomed Inform; 2019 Aug; 96():103253. PubMed ID: 31325501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Research on drug safety and effectiveness using pharmacoepidemiological databases.
    Andersen M
    J Intern Med; 2014 Jun; 275(6):548-50. PubMed ID: 24635741
    [No Abstract]   [Full Text] [Related]  

  • 32. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical Appraisal of Observational Designs.
    Quincy B; Ragan P
    J Physician Assist Educ; 2017 Mar; 28(1):49-52. PubMed ID: 28207583
    [No Abstract]   [Full Text] [Related]  

  • 34. Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance.
    Silva IR; Kulldorff M
    Biometrics; 2015 Sep; 71(3):851-8. PubMed ID: 26011024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system.
    Suchard MA; Zorych I; Simpson SE; Schuemie MJ; Ryan PB; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S83-93. PubMed ID: 24166226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design considerations in an active medical product safety monitoring system.
    Gagne JJ; Fireman B; Ryan PB; Maclure M; Gerhard T; Toh S; Rassen JA; Nelson JC; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():32-40. PubMed ID: 22262591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.
    Patorno E; Garry EM; Patrick AR; Schneeweiss S; Gillet VG; Zorina O; Bartels DB; Seeger JD
    Drug Saf; 2015 Mar; 38(3):295-310. PubMed ID: 25761856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research challenges: overview of epidemiological study designs.
    Bombardier C
    J Rheumatol Suppl; 1988 Oct; 17():5-8. PubMed ID: 3204620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to comment on 'empirical assessment of methods for risk identification in healthcare data'.
    Ryan PB; Madigan D; Stang PE; Marc Overhage J; Racoosin JA; Hartzema AG
    Stat Med; 2013 Mar; 32(6):1075-7. PubMed ID: 23413215
    [No Abstract]   [Full Text] [Related]  

  • 40. Decision making in drug safety-a literature review of criteria used to prioritize newly detected safety issues.
    Pacurariu AC; Coloma PM; Gross-Martirosyan L; Sturkenboom MC; Straus SM
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):327-334. PubMed ID: 27878889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.